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Summary The pattern of spontaneous screening for cervical cancer by general practitioners and
gynaecologists in The Netherlands is compared with an efficient screening policy resulting from a cost-effective
study. Spontaneous screening tends to start and stop too early in a woman's life, and leaves too many women
overscreened or unprotected. The combination in young age of a low incidence of invasive cancer and a high
incidence of regressive lesions explains relative ineffectiveness and harmfulness of present screening practice.
When screening would take place between ages 30 and at least 60, with intervals of about 5 years, as many
lives could be saved for half the costs and with only 60% of the unnecessary referrals and treatments. Much
attention should be paid to the coverage of the target population. Therapeutic follow-up policies for dysplastic
lesions should be restrained.
Screening has contributed to the decrease in cervical cancer
mortality in several countries (Day 1986a, Hakama, 1985;
Laara et al., 1987; Day, 1984; van der Graaf et al., 1988).
There is still debate on the age to start screening and on the
interval. Some screening recommendations call for intensive
screening at a young age (ACOG, 1980; CTF, 1982) but
studies which analyse the health effects of screening conclude
that screening efforts should be directed to middle aged and
older women (Liiara et al., 1987; Knox, 1976; Miller, 1985;
Day, 1986b; Parkin et al., 1986). The advocated interval has
been lengthening the last few years but in practice the interval
tends to be still short.
The pros and cons of screening policies critically depend
on the duration and detectability of the preclinical stages of
the disease. Knowledge of these important parameters can be
derived from the results of existing screening programmes.
Therefore, a detailed analysis was made of data from the
early detection programmes in British Columbia and in The
Netherlands. Both analyses led to very similar conclusions
(Habbema et al., 1985). The first one has been published
recently in this journal (van Oortmarssen, 1991).
In this article we study the consequences of the results on
duration and regression for balanced Pap-smear taking. We
compare spontaneous screening with optimised screening,
studying the costs, risks and benefits.
Methods and materials
The natural history
For The Netherlands, the following estimates were derived:
- a smear will detect 70% of the cases of cervical intra-
epithelial neoplasia (CIN) III (sensitivity, that pertains to the
situation in which women with at least (cytologically)
moderate dysplasia twice or severe dysplasia once are refer-
red for colposcopy);
- 0.4% of the smears will be false-positive (no CIN, or at the
most CIN II will be found histologically).
- the mean duration of CIN III is 15 years;
- on average 60% of the cases of CIN III will regress
spontaneously, this percentage is highest at younger age (see
Figure 1);
- a higher incidence of cervical cancer in non-attenders to
screening than in attenders.
Predictive calculations
The assumptions on natural history have been implemented
in a computerised epidemiometric model, which uses also
assumptions on demography, age-specific incidence and stage-
specific survival (see Habbema et al., 1987 for a full descrip-
tion of the model). Screening policies were assumed to be
operational in The Netherlands in the period 1988-2015.
Health effects and changes in number of women referred and
treated after the termination of the programme have also
been taken into account.
Outcomes are effectiveness (number of life years gained),
costs (number of screenings) and risks (the number of women
unnecessarily referred and treated because of false positive
test results or regressive lesions). All these results have been
calculated as differences with the (hypothetical) situation in
which there is no early detection of cervical cancer.
As we emphasise the ratio between positive and negative
effects, for which discounting is disputable, undiscounted
results are presented. The comparison between different
policies is only very little affected by discounting.
Spontaneous screening
Spontaneous screening has been defined as screening in the
situation without any invitational programme, resulting from
the existing diversity of initiatives among the women and the
doctors involved. We studied data on screening by general
practitioners and gynaecologists in The Netherlands during
the period 1985-1988, during which there were almost no
invitational screening programmes running. We found (see
Figure 2) that it starts at very young ages, declines in inten-
sity after age 35 and stops nearly entirely at age 55-60.
Population coverage is rather poor at older ages. This pat-
tern corresponds with reports of other European and North
American countries (Kjellgren, 1986; Hakulinen & Hakama,
1985; Choi & Nelson, 1986; Anderson et al., 1988; Parkin et
al., 1982). Detailed data on individual screening patterns in
spontaneous screening were not available. We assumed that
50% of the screened women have a smear every 2 years, the
others being screened less often. The spontaneous screening
pattern was incorporated in our model and the costs, risks
and benefits were calculated.
Results
Efficient and spontaneous screening compared
We identified the efficient (with the lowest costs) screening
policy with 65% attendance that results in the same number
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Figure 1 Age-specific prevalence of CIN III (histologically
confirmed severe dysplasia or carcinoma in situ) in the un-
screened population. Estimates which are based on observed data
from cervical cancer screening programmes in The Netherlands
(see text). Speculative under age 30 (few data available).
of life-years gained as the spontaneous screening pattern
described. We assumed a 65% attendance level (percentage
of the women screened) because this was reached in centrally
organised screening with a population based invitation
system in Dutch pilot regions (EVAC 1989). The efficient
policy differs from spontaneous screening in four ways (see
Figure 2):
- there is no screening in very young women: starting age is
33 years;
- women are screened until later in life: ending age is 68
years;
- the interval is longer: 5 years;
- coverage is higher, especially in older women.
Costs, risks and benefits of both screening patterns are pre-
sented in Table I. The efficient policy requires half the number
of smears to reach the same number of life-years gained as
spontaneous screening, and the adverse effects will be cut
down by more than 40%.
In order to explore the reasons for these large differences
in risks and benefits, we will now have a detailed look at the
four characteristics of efficient screening mentioned.
Screening at a young age
The isolated effect of screening at young age vs screening
later in life is demonstrated for the case of a single screening
(see Table II). With a single invitation at age 40, the number
of women unnecessarily referred for CIN III or lesser abnor-
malities and unnecessarily treated for each death avoided are
seven and five times lower than with a single screening
invitation at age 20. The chance that a first screened woman
has a CIN III is highest at young age (continuous line in
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Figure 2 Two screening patterns: annually percentage of the female
population screened by age. I. Spontaneous screening pattern by
general practitioners and gynaecologists (see text). II. Efficient screen-
ing pattern (see text): age 33 to 68 every 5 years, attendance 65%.
Table I Results: number of smears and the major effects of two
different approaches to cervical cancer screening. All numbers are
per million women per year
Life- Unnecessarily
Screening years Deaths Women treated
patterns Smearsc gained avoided referred womend
Spontaneousa 120.000 400 14 370 135
Efficientb 65.000 400 18 210 80
aSpontaneous screening pattern by general practitioners and
gynaecologists. "Efficient pattern, age 33 to 68, every 5 years,
attendance 65%. cSee Figure 2 for the age distribution of the smears.
dAt least local treatment (e.g. cryocoagulation or laser-evaporation).
Table II Results: number of smears and the major effects of
different cervical cancer screening patterns. All numbers are per
million women per year
Life- Unnecessarily
Screening years Deaths Women treated
patterns Smears gained avoided referred womene
Young ages:a
1 smear at 20 9.000 20 0.4 30 10
1 smear at 40 10.500 110 4 40 20
Old ages:b
until age 68 65.000 400 18 210 80
until age 51 67.500 340 12 220 90
Intervals:c
every 8 years 37.000 260 13 120 45
every 2 years 196.000 580 27 600 210
Attendance:d
100%, 5x 51.000 450 23 170 65
50%, 25x 129.000 440 20 400 140
aSingle screening at age 20, attendance 75%. Single screening at
age 40, attendance 75% respectively. bEfficient pattern, age 33 to 68,
every 5 years, attendance 65%. Screening from age 33 to 51, every 3
years, attendance 65% respectively. cEfficient pattern, age 39 to 71,
every 8 years, attendance 65%. Efficient pattern, age 26 to 74, every
2 years, attendance 65% respectively. dEfficient pattern, age 39 to 71,
every 8 years, attendance 100%. Efficient pattern, age 26 to 74, every
year, attendance 50% respectively. eAt least local treatment (e.g.
cryocoagulation or laser-evaporation).
Figure 1). As women with diagnosed CIN III are nearly
always treated, regression (discontinuous line in Figure 1)
can not be observed.
The long duration of progressive CIN III (about 15 years
on average) results in timely detection in the large majority
of the cases when screening starts at age 30. Thus, only a few
deaths will be avoided by additional screening under 30
years, at the expense of a very large number of screenings
and a considerable risk of treatment of regressive lesions.
We basically assumed a stable incidence of cervical cancer
for the birth cohorts from 1948 onwards. Even when we
assumed an increase in the incidence for women born after
1960 with 50%, the starting age of the efficient policies still
did not fall much under 30.
Screening in old age
To study the difference in results with and without screening
women between 50 and 70, we compared two screening
policies that both start at age 33, the one (already presented
in Table I) ending at age 68, the other at age 51 (see Table
II). The latter policy is certainly not efficient: 15% more
life-years can be gained with even less (5%) screenings when
the policy is extended to the age-group 51-68 by increasing
the interval from 3 to 5 years.
Is the chance that a woman will develop cervical cancer
later negligible when she reached the age of 50 without
developing a precursor of cervical cancer? When this would
be true, the high death rate in old age could only be caused
by poor screening under 50 years. Available epidemiologic
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data suggest otherwise. The detection rate for preinvasive
plus invasive cancer in women who were first screened
between 50 and 55 years in Nijmegen and Utrecht (Collette,
1974) was 4.1-7.6 per 1,000. This is clearly less than the
cumulative incidence of invasive cancer of 11.8 per 1,000
women of age 55-84 in 1975, i.e. before screening became
widespread (Smid, 1983). The gap between detection rate and
cumulative incidence can only partly be explained by a sensi-
tivity of the pap-smear of e.g. 70%.
The poor screening history in women over age 50 is in
itself reason enough to screen until at least age 65 during the
forthcoming decade (Fletcher, 1990; Muller, 1990). Mean-
while, new evidence could be collected on incidence in older
women and on the need for further screening in women who
received adequate screening until age 50-55.
The interval between successive screenings
The effect of screening frequency is quantified by comparing
intervals of2 and 8 years (see Table II). With an interval of 8
years 2,800 smears are needed per death avoided. With an
interval of 2 years this number rises to 7,300 smears. The
reason is that the chance of getting invasive cancer decreases
substantially by a screening in the previous 2-3 years (see
Figure 3). As pointed out in the report of the IARC working
group (Day, 1986a), this decrease can be seen in data from
screening programs even 10 years after a negative screening.
This is not surprising with a mean duration of CIN III of 15
years.
The balance between risks and benefits also gets worse.
With an interval of 8 years, nine women are referred and
three women are treated per death avoided. With an interval
of 2 years, these numbers increase to 22 women referred and
eight women treated.
The coverage ofthe targetpopulation
As shown in Table II, cervical cancer mortality would be
lower when all women would have a pap-smear five times in
their life, than when 50% of the women would be screened
25 times. Most cases of invasive cervical cancer nowadays
occur in unscreened or poorly screened women (La Vecchia
et al., 1987). Incidence in non-attenders appears to be higher
than in the total population. This conclusion of our analysis
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of the Canadian and Dutch screening data is supported by
data from Denmark and Norway (Berget, 1979; Magnus,
1987). A further reduction in mortality can primarily be
achieved by screening the as yet unscreened women. The use
of a shorter screening interval would mainly result in a more
frequent screening of those who are already being screened.
Discussion
A comparable study has been performed by Eddy (Eddy,
1990). Although his outcomes show a very small difference in
effectiveness when lengthening the interval from 1 to 4 years,
he surprisingly recommmends screening at least every 3 years.
Eddy recommends to start screening in the early 20s, without
studying adverse effects and assuming an age-independent
regression rate. In our view high regression rates at young
age cause extra risks of screening for young women.
Follow-up and treatment
Cervical cancer screening will always induce unnecessary
treatment, because of the partly regressive nature of CIN.
The seriousness of this adverse effect depends on the treat-
ment applied. We found that in some Dutch gynaecological
centers nearly 50% of the women with CIN III were treated
with hysterectomy and in other centers 10% (van Ballegooi-
jen et al., 1990). From the USA, hysterectomy rates in
women with cervical carcinoma in situ are reported to be
50% (Goodwin et al., 1990). In a screening programme with
excellent gynaecological follow-up, the number of hysterec-
tomies for cervical cancer in the population should fall
because of the decreasing number of invasive cancers. But
with an excessively aggressive treatment of preinvasive
lesions, the number of hysterectomies can increase 3-fold
when an intensive screening programme is carried out.
Conclusions
Our analysis clearly shows the consequences of screening
efforts still starting and stopping too early in life, and being
performed too frequently. The importance of a high coverage
cannot be overemphasised.
Numberof previous screenings
Figure 3 Relative risk of invasive cervical cancer in screened women with a most recent screening 2-3 years ago compared to
unscreened women. Calculated from (Day, 1986a).
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